Clinical trial · Observational
Analysis of Plasma Tumor DNA in Lung Cancer Patients
Analysis of Mechanism of Resistance to Chemotherapy by Sequencing of Plasma DNA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The presence of genetic alterations in the tyrosine kinase domain of the oncogene (eg. EGFR and ALK) is associated with the clinical response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancers. Therefore, the detection of altered genetic alterations is useful for predicting the treatment response for TKIs in non-small cell lung cancer patients. However, good quality tumor tissues are available only in \<50% of patients with inoperable lung cancer for mutation analysis. In this study, the investigators will detect and quantify the genetic alterations in plasma. the investigators will investigate if the serial measurement of cancer-derived genetic alterations in plasma can provide a means for monitoring disease progression, as well as treatment response. In addition the investigators will analysis the resistant mechanism of TKIs and chemotherapy with plasma tumor DNA.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer Patients | Lung Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Detection of genetic alterations (including EGFR and ALK) in plasma samples
- timeFrame
- 60 months
- description
- To evaluate the sensitivity of digital PCR to detect the genetic alterations in plasma tumor DNA
Secondary outcomes (1)
- measure
- Quantifying circulating tumor DNA in serially collected plasma specimens
- timeFrame
- 60 months
- description
- To evaluate the change of quantity of circulating tumor DNA with digital PCR
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Have a histologically or cytologically confirmed diagnosis of non-small cell lung cancer * Have molecular evidence of genetic alterations in tumor sample (eg. EGFR mutations, ALK fusions) * Patients must have given written informed consent Exclusion Criteria: * Patients who refuse the blood samplings
References
Publications (0)
Data not yet available